ArticleClinical and experimental nephrology2022
Long-term outcomes of IgA nephropathy patients with less than 25% crescents and mild proteinuria.
Article in Clinical and experimental nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Lower proteinuria is better for patients with IgA nephropathy: a systematic review.Frontiers in nephrology · 2025Pooled it
- Presence of crescents in IgA nephropathy-prediction from ultrasound images using deep learning.BMC medical imaging · 2025Article
- The importance of the degree of foot process effacement in evaluating the prognosis of IgA nephropathy.International urology and nephrology · 2025Article
- Potential of serum sulfatide levels as a marker for classification and disease activity in lupus nephritis.Frontiers in immunology · 2025Article
- Relationship between IgM deposition in the mesangial region and the prognosis of IgA nephropathy: a single-centre retrospective study.BMC nephrology · 2024Article
- Interpretable Machine Learning Model Based on Superb Microvascular Imaging for Non-Invasive Determination of Crescent Status of IgAN.Journal of inflammation research · 2024Article
- Histologic evaluation of activity and chronicity of lupus nephritis and its clinical significance.Kidney research and clinical practice · 2023Article
- A novel clinical-radiomic nomogram for the crescent status in IgA nephropathy.Frontiers in endocrinology · 2023Article
- Crescents and IgA Nephropathy: A Delicate Marriage.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundWhether immunosuppressive therapy in IgA nephropathy (IgAN) patients with less than 25% crescents (C1) and mild proteinuria can improve the renal outcome is still unclear.
methodsWe recruited 140 IgAN patients with C1 and proteinuria < 1 g/24 h who received supportive care (n = 52) or steroid-based immunosuppressive therapy (n = 88) in Xijing Hospital from July 2008 to December 2016. The primary outcome was the rate of renal function decline.
resultsThe median of proteinuria was 575.5 mg/24 h, the fraction of crescents was 7% (5%, 12%) and follow-up time was 69.1 months. The rate of renal function decline [0.5 (- 1.5, 3.2) vs - 0.7 (- 3.5, 0.5) ml/min per 1.73 m
conclusionSteroid-based immunosuppressive therapy may slow down the rate of renal function decline of IgAN patients with C1 and proteinuria ≤ 1 g/24 h.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.